Skip to main content

Advertisement

SpringerLink
Log in

Update on Neuropathic Pain Treatment: Ion Channel Blockers and Gabapentinoids

  • Neuropathic Pain (E Eisenberg, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat. The current mainstays of treatment include physical therapy, interventional procedures and medications. Among medications, ion channel blockers and gabapentinoids are the 2 classes of drugs commonly used to treat neuropathic pain. It has been suggested that these medications may be useful to treat a variety of neuropathic pain conditions. This article provides several updates on the utility of both ion channel blockers and gabapentinoids for the treatment of neuropathic pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5. doi:10.1212/01.wnl.0000282763.29778.59.

    Article  PubMed  CAS  Google Scholar 

  2. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–21. doi:10.1016/j.jpain.2007.09.005.

    Article  PubMed  Google Scholar 

  3. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14. doi:10.4065/mcp.2009.0649.

    Article  PubMed  CAS  Google Scholar 

  4. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. J Pain. 2006;7:281–9. doi:10.1016/j.jpain.2005.11.008.

    Article  PubMed  Google Scholar 

  5. •• Mao J. Current challenges in translational pain research. Trends Pharmacol Sci. 2012;33:568–73. doi:10.1016/j.tips.2012.08.001. This article discusses the achievements and challenge in pain research, pain management, and development of new analgesics. The article also comments on future directions of translational pain research..

    Article  PubMed  CAS  Google Scholar 

  6. •• Vorobeychik Y, Gordin V, Mao J, Chen L. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011;25:1023–34. doi:10.2165/11596280-000000000-00000. This article lists a variety of combinations of medications that are used to treat neuropathic pain conditions. It also discusses the rationale and outcome of combination drug therapy for pain management..

    Article  PubMed  CAS  Google Scholar 

  7. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81:1372–3. doi:10.1136/jnnp.2008.144964.

    Article  PubMed  Google Scholar 

  8. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9:2209–15. doi:10.1517/14656566.9.12.2209.

    Article  PubMed  CAS  Google Scholar 

  9. •• Mao J, Gold MS, Backonja MM. Combination drug therapy for chronic pain: a call for more clinical studies. J Pain. 2011;12:157–66. doi:10.1016/j.jpain.2010.07.006. In this article, the authors discuss the challenges in using combination drug therapy. The authors called for further investigation in both preclinical clinical areas..

    Article  PubMed  CAS  Google Scholar 

  10. Sinatra R. The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin Pharmacokinet. 2005;44 Suppl 1:1–6.

    Article  PubMed  CAS  Google Scholar 

  11. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5:315–23. doi:10.1586/14737175.5.3.315.

    Article  PubMed  CAS  Google Scholar 

  12. Kaplan KM, Brose WG. Intrathecal methods. Neurosurg Clin N Am. 2004;15:289–96. doi:10.1016/j.nec.2004.02.011.

    Article  PubMed  Google Scholar 

  13. Simpson Jr RK. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am. 2003;14:353–64.

    Article  PubMed  Google Scholar 

  14. Bennett G, Deer T, Du Pen S, Rauck R, Yaksh T, Hassenbusch SJ. Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manag. 2000;20:S44–50.

    Article  CAS  Google Scholar 

  15. Yaksh TL. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sci. 1999;20:329–37.

    Article  PubMed  CAS  Google Scholar 

  16. Yaksh TL. New horizons in our understanding of the spinal physiology and pharmacology of pain processing. Semin Oncol. 1993;20(2 Suppl 1):6–18.

    PubMed  CAS  Google Scholar 

  17. Yaksh TL. Spinal pharmacology of pain and its modulation. Clin Neurosurg. 1983;31:291–303.

    PubMed  CAS  Google Scholar 

  18. Coluzzi PH. Sublingual morphine: efficacy reviewed. J Pain Symptom Manag. 1998;16:184–92.

    Article  CAS  Google Scholar 

  19. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 2005;6:225–34. doi:10.1111/j.1526-4637.2005.05035.x.

    Article  PubMed  Google Scholar 

  20. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ. Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003;55:683–9.

    Article  PubMed  CAS  Google Scholar 

  21. Drake Jr ME, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol. 2004;27:278–80.

    Article  PubMed  CAS  Google Scholar 

  22. Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. J Pain. 2004;5:192–4. doi:10.1016/j.jpain.2004.01.002.

    Article  PubMed  Google Scholar 

  23. • Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev. 2012;64:887–95. doi:10.1016/j.addr.2011.11.006. This article provides a summary of antiepileptic drugs, most of which are also used for chronic pain management, including neuropathic pain..

    Article  PubMed  CAS  Google Scholar 

  24. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008;4:493–506. doi:10.1517/17425255.4.4.493.

    Article  PubMed  CAS  Google Scholar 

  25. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009;9:327–37. doi:10.1111/j.1533-2500.2009.00303.x.

    Article  PubMed  Google Scholar 

  26. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy. 2005;25:1084–94. doi:10.1592/phco.2005.25.8.1084.

    Article  PubMed  CAS  Google Scholar 

  27. • Backonja MM. Neuropathic pain therapy: from bench to bedside. Semin Neurol. 2012;32:264–8. doi:10.1055/s-0032-1329204. This article summarizes the current data regarding translational research on neuropathic pain treatment..

    Article  PubMed  Google Scholar 

  28. Michiels WB, McGlthlen GL, Platt BJ, Grigsby EJ. Trigeminal neuralgia relief with intrathecal ziconotide. Clin J Pain. 2011;27:352–4. doi:10.1097/AJP.0b013e3181fb22f4.

    Article  PubMed  Google Scholar 

  29. Lukyanetz EA, Sotkis AV, Kostyuk PG. Mechanisms of up-regulation of single calcium channels by serotonin in helix pomatia neurons. Biochem Biophys Res Commun. 2002;293:132–8. doi:10.1016/S0006-291X(02)00195-X.

    Article  PubMed  CAS  Google Scholar 

  30. Jungehulsing GJ, Israel H, Safar N, et al. Levetiracetam in patients with central neuropathic poststroke pain--a randomized, double-blind, placebo-controlled trial. Eur J Neurol. 2013;20:331–7. doi:10.1111/j.1468-1331.2012.03857.x.

    Article  PubMed  CAS  Google Scholar 

  31. Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. Eur J Pain. 2011;15:608–14. doi:10.1016/j.ejpain.2010.11.007.

    Article  PubMed  CAS  Google Scholar 

  32. Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurother. 2010;10:159–71. doi:10.1586/ern.10.5; 10.1586/ern.10.5.

    Article  PubMed  CAS  Google Scholar 

  33. Waxman SG, Cummins TR, Dib-Hajj S, Fjell J, Black JA. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve. 1999;22:1177–87.

    Article  PubMed  CAS  Google Scholar 

  34. Quasthoff S, Grosskreutz J, Schroder JM, Schneider U, Grafe P. Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibers of biopsied human sural nerve. Neuroscience. 1995;69:955–65.

    Article  PubMed  CAS  Google Scholar 

  35. Stebbing MJ, Eschenfelder S, Habler HJ, Acosta MC, Janig W, McLachlan EM. Changes in the action potential in sensory neurones after peripheral axotomy in vivo. Neuroreport. 1999;10:201–6.

    Article  PubMed  CAS  Google Scholar 

  36. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87:7–17.

    Article  PubMed  CAS  Google Scholar 

  37. Nikolajsen L, Black JA, Kroner K, Jensen TS, Waxman SG. Neuroma removal for neuropathic pain: efficacy and predictive value of lidocaine infusion. Clin J Pain. 2010;26:788–93.

    Article  PubMed  Google Scholar 

  38. Petersen P, Kastrup J, Zeeberg I, Boysen G. Chronic pain treatment with intravenous lidocaine. Neurol Res. 1986;8:189–90.

    PubMed  CAS  Google Scholar 

  39. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin. 2004;20 Suppl 2:S21–8. doi:10.1185/030079904X12960.

    Article  PubMed  CAS  Google Scholar 

  40. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5 % in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin. 2004;20 Suppl 2:S5–S12. doi:10.1185/030079904X12933.

    Article  PubMed  CAS  Google Scholar 

  41. Meier T, Faust M, Huppe M, Schmucker P. Reduction of chronic pain for nonpostherpetic peripheral neuropathies after topical treatment with a lidocaine patch. Schmerz. 2004;18:172–8. doi:10.1007/s00482-003-0272-4.

    Article  PubMed  CAS  Google Scholar 

  42. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64:937–47.

    Article  PubMed  CAS  Google Scholar 

  43. Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5 % for chronic low back pain: a report of 4 cases. Pain Med. 2002;3:361–5. doi:10.1046/j.1526-4637.2002.02051.x.

    Article  PubMed  Google Scholar 

  44. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32. doi:10.1016/j.amjmed.2009.04.007.

    Article  PubMed  Google Scholar 

  45. Davis RW. Successful treatment for phantom pain. Orthopedics. 1993;16:691–5.

    PubMed  CAS  Google Scholar 

  46. Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005;115:e504–7. doi:10.1542/peds.2004-1395.

    Article  PubMed  Google Scholar 

  47. Sjogren P, Banning AM, Hebsgaard K, Petersen P, Gefke K. Intravenous lidocaine in the treatment of chronic pain caused by bone metastases. Ugeskr Laeger. 1989;151:2144–6.

    PubMed  CAS  Google Scholar 

  48. Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia. 2003;23:963–71.

    Article  PubMed  CAS  Google Scholar 

  49. Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44:45–8.

    Article  PubMed  CAS  Google Scholar 

  50. Sandner-Kiesling A, Rumpold Seitlinger G, Dorn C, Koch H, Schwarz G. Lamotrigine monotherapy for control of neuralgia after nerve section. Acta Anaesthesiol Scand. 2002;46:1261–4.

    Article  PubMed  CAS  Google Scholar 

  51. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375–83.

    Article  PubMed  CAS  Google Scholar 

  52. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508–14.

    Article  PubMed  CAS  Google Scholar 

  53. • Cruccu G, Truini A. Refractory trigeminal neuralgia. nonsurgical treatment options. CNS Drugs. 2013;27:91–6. doi:10.1007/s40263-012-0023-0. This article lists medications that have been used for the treatment of trigeminal neuralgia..

    Article  PubMed  Google Scholar 

  54. Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1989;52:472–6.

    Article  PubMed  CAS  Google Scholar 

  55. Gomez-Arguelles JM, Dorado R, Sepulveda JM, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci. 2008;15:516–9. doi:10.1016/j.jocn.2007.04.010.

    Article  PubMed  CAS  Google Scholar 

  56. Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain. 2004;20:174–8.

    Article  PubMed  Google Scholar 

  57. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006;113:395–404. doi:10.1111/j.1600-0404.2006.00631.x.

    Article  PubMed  CAS  Google Scholar 

  58. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543–54. doi:10.1016/j.ejpain.2004.11.006.

    Article  PubMed  CAS  Google Scholar 

  59. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurol Scand. 2005;111:229–32. doi:10.1111/j.1600-0404.2005.00300.x.

    Article  PubMed  CAS  Google Scholar 

  60. Lalwani K, Shoham A, Koh JL, McGraw T. Use of oxcarbazepine to treat a pediatric patient with resistant complex regional pain syndrome. J Pain. 2005;6:704–6. doi:10.1016/j.jpain.2005.05.005.

    Article  PubMed  CAS  Google Scholar 

  61. Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther. 2005;27:1420–31. doi:10.1016/j.clinthera.2005.09.011.

    Article  PubMed  CAS  Google Scholar 

  62. Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from 3 double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221–31.

    Article  PubMed  CAS  Google Scholar 

  63. Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. Curr Treat Options Neurol. 2013;15:56–62. doi:10.1007/s11940-012-0205-6.

    Article  PubMed  Google Scholar 

  64. Wang QP, Bai M. Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia: a meta-analysis. CNS Drugs. 2011;25:847–57. doi:10.2165/11595590-000000000-00000.

    Article  PubMed  CAS  Google Scholar 

  65. Mao J, Chen LL. Gabapentin in pain management. Anesth Analg. 2000;91:680–7.

    Article  PubMed  CAS  Google Scholar 

  66. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936–45. doi:10.1210/jc.2004-2376.

    Article  PubMed  CAS  Google Scholar 

  67. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–6.

    Article  PubMed  CAS  Google Scholar 

  68. Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1999;40 Suppl 6:S57–9. discussion S73–4.

    Article  PubMed  CAS  Google Scholar 

  69. Paradowski B, Bilinska M. Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus. Pol Merkur Lek. 2003;15:61–4.

    Google Scholar 

  70. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931–7.

    Article  PubMed  CAS  Google Scholar 

  71. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manag. 2000;20:280–5.

    Article  CAS  Google Scholar 

  72. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manag. 2000;20:449–58.

    Article  CAS  Google Scholar 

  73. Backonja MM. Neuropathic pain therapy: from bench to bedside. Semin Neurol. 2012;32:264–8. doi:10.1055/s-0032-1329204.

    Article  PubMed  Google Scholar 

  74. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34. doi:10.1056/NEJMoa042580.

    Article  PubMed  CAS  Google Scholar 

  75. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–42.

    Article  PubMed  CAS  Google Scholar 

  76. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain. 2001;94:215–24.

    Article  PubMed  CAS  Google Scholar 

  77. Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from 3 clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2:157–62. doi:10.1016/j.amjopharm.2004.09.004.

    Article  PubMed  CAS  Google Scholar 

  78. Rauck RL, Irving GA, Wallace MS, Vanhove GF, Sweeney M. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from 2 phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manag. 2012. doi:10.1016/j.jpainsymman.2012.07.011.

    Google Scholar 

  79. Beal B, Moeller-Bertram T, Schilling JM, Wallace MS. Gabapentin for once-daily treatment of postherpetic neuralgia: a review. Clin Interv Aging. 2012;7:249–55. doi:10.2147/CIA.S23783.

    PubMed  CAS  Google Scholar 

  80. Kanodia SK, Seth AK, Dixit AM. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients. Indian J Dermatol. 2012;57:362–5. doi:10.4103/0019-5154.100476.

    Article  PubMed  Google Scholar 

  81. Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in hemodialysis patients. Clin Drug Investig. 2013. doi:10.1007/s40261-013-0080-2.

    PubMed  Google Scholar 

  82. Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29:863–9. doi:10.1007/s40266-012-0014-3.

    Article  PubMed  CAS  Google Scholar 

  83. Kawasaki M, Hatashima S, Matsuda T. Nonsurgical therapy for bilateral glossopharyngeal neuralgia caused by eagle's syndrome, diagnosed by three-dimensional computed tomography: a case report. J Anesth. 2012;26:918–21. doi:10.1007/s00540-012-1437-z.

    Article  PubMed  Google Scholar 

  84. Ozgencil E, Yalcin S, Tuna H, Yorukoglu D, Kecik Y. Perioperative administration of gabapentin 1200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomized, double-blinded, placebo-controlled study. Singap Med J. 2011;52:883–9.

    CAS  Google Scholar 

  85. Jensen MP, Irving G, Rauck R, Wallace M, Sweeney M, Vanhove GF. Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. Clin J Pain. 2013. doi:10.1097/AJP.0b013e31827b32ab.

    Google Scholar 

  86. Argoff CE, Chen C, Cowles VE. Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. Expert Opin Drug Deliv. 2012;9:1147–60. doi:10.1517/17425247.2012.709231.

    Article  PubMed  CAS  Google Scholar 

  87. Sang CN, Sathyanarayana R, Sweeney M. DM-1796 Study Investigators. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013;29:281–8. doi:10.1097/AJP.0b013e318258993e.

    Article  PubMed  Google Scholar 

  88. Singh PM, Dehran M, Mohan VK, Trikha A, Kaur M. Analgesic efficacy and safety of medical therapy alone vs combined medical therapy and extraoral glossopharyngeal nerve block in glossopharyngeal neuralgia. Pain Med. 2013;14:93–102. doi:10.1111/pme.12001.

    Article  PubMed  Google Scholar 

  89. Miyazaki R, Yamamoto T. The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. Anesth Analg. 2012;115:182–8. doi:10.1213/ANE.0b013e31824f94ca.

    Article  PubMed  CAS  Google Scholar 

  90. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–10.

    Article  PubMed  CAS  Google Scholar 

  91. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35:2451–8. doi:10.2337/dc12-0656; 10.2337/dc12-0656.

    Article  PubMed  CAS  Google Scholar 

  92. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs. 2005;65:111–8. discussion 119–20.

    Article  PubMed  Google Scholar 

  93. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs. 2004;64:2813–20. discussion 2821.

    Article  PubMed  CAS  Google Scholar 

  94. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient Function/Quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013. doi:10.1016/j.clinthera.2013.03.008.

    PubMed  Google Scholar 

  95. Achar A, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol Croat. 2012;20:89–94.

    PubMed  CAS  Google Scholar 

  96. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73. doi:10.1002/art.20983.

    Article  PubMed  CAS  Google Scholar 

  97. Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract. 2013. doi:10.1111/papr.12045; 10.1111/papr.12045.

    PubMed  Google Scholar 

  98. de Salas-Cansado M, Perez C, Saldana MT, Navarro A, Rejas J. A cost-effectiveness analysis of the effect of pregabalin vs usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain. Pain Med. 2012;13:699–710. doi:10.1111/j.1526-4637.2012.01375.x.

    Article  PubMed  Google Scholar 

  99. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80:533–9. doi:10.1212/WNL.0b013e318281546b.

    Article  PubMed  CAS  Google Scholar 

  100. Singh RK, Sinha VP, Pal US, Yadav SC, Singh MK. Pregabalin in post-traumatic neuropathic pain: case studies. Natl J Maxillofac Surg. 2012;3:91–5. doi:10.4103/0975-5950.102175.

    Article  PubMed  Google Scholar 

  101. Saldana MT, Perez C, Navarro A, Masramon X, Rejas J. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. Clin Drug Investig. 2012;32:401–12. doi:10.2165/11599400-000000000-00000.

    Article  PubMed  CAS  Google Scholar 

  102. Jensen MP, Gammaitoni AR, Bolognese JA, et al. The pain quality response profile of pregabalin in the treatment of neuropathic pain. Clin J Pain. 2012;28:683–6. doi:10.1097/AJP.0b013e31823f9e64.

    Article  PubMed  Google Scholar 

  103. Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013. doi:10.1007/s00228-012-1464-6.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Lucy Chen declares that she has no conflict of interest. Jianren Mao declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Lucy Chen & Jianren Mao

Authors
  1. Lucy Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianren Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianren Mao.

Additional information

This article is part of the Topical Collection on Neuropathic Pain

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, L., Mao, J. Update on Neuropathic Pain Treatment: Ion Channel Blockers and Gabapentinoids. Curr Pain Headache Rep 17, 359 (2013). https://doi.org/10.1007/s11916-013-0359-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-013-0359-2

Keywords

Search

Navigation